Ebola-specific therapeutic antibodies from lab to clinic: The example of ZMapp

In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antiviral research Jg. 226; S. 105873
Hauptverfasser: Wong, Gary, Bienes, Kathrina Mae, XIII, Ara, Fausther-Bovendo, Hugues, Kobinger, Gary P.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Netherlands Elsevier B.V 01.06.2024
Schlagworte:
Africa, Western - epidemiology
Animals
Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - therapeutic use
Antibodies, Neutralizing - immunology
Antibodies, Neutralizing - therapeutic use
Antibodies, Viral - immunology
Antibodies, Viral - therapeutic use
Disease Outbreaks
Ebola Virus
Ebolavirus - drug effects
Ebolavirus - immunology
EBOV
Hemorrhagic Fever, Ebola - drug therapy
Hemorrhagic Fever, Ebola - immunology
Humans
mAbs
Monoclonal antibodies
ZMapp
Africa, Western
Monoclonal antibodies
EBOV
Ebola Virus
ZMapp
mAbs
ISSN:0166-3542, 1872-9096, 1872-9096
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In the 1990s, monoclonal antibodies (mAbs) progressed from scientific tools to advanced therapeutics, particularly for the treatment of cancers and autoimmune and inflammatory disorders. In the arena of infectious disease, the inauguration of mAbs as a post-exposure treatment in humans against Ebola virus (EBOV) occurred in response to the 2013–2016 West Africa outbreak. This review recounts the history of a candidate mAb treatment, ZMapp, beginning with its emergency use in the 2013–2016 outbreak and advancing to randomized controlled trials into the 2018–2020 African outbreak. We end with a brief discussion of the hurdles and promise toward mAb therapeutic use against infectious disease.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0166-3542
1872-9096
1872-9096
DOI:10.1016/j.antiviral.2024.105873